All patients
Age < 65y (younger) Age > 65y Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 hemoglobin concentration > 10g/dl PD-L1 < 1% PD-L1 > 1% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
ovarian cancer (OC), immune chekpoint inhibitors vs. pegylated liposomal doxorubicin, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.14 [0.88; 1.47]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.89 [0.69; 1.15]
1.01 [0.79 ; 1.29 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 44% 756 moderate not evaluable progression or deaths (PFS)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.68 [1.20; 2.36]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.78 [0.54; 1.13]
1.15 [0.54 ; 2.44 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 89% 756 moderate not evaluable DCRdetailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 2.02 [1.33; 3.07]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2.79 [1.83; 4.24]
2.37 [1.73 ; 3.25 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 12% 756 moderate not evaluable objective responses (ORR)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.89 [0.27; 2.92]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.46 [1.39; 8.64]
1.85 [0.49 ; 6.98 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 68% 756 moderate not evaluable TRAE (any grade)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.45 [0.26; 0.76]
0.45 [0.26 ; 0.76 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021 1 0% 364 NA not evaluable TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.41 [0.24; 0.68]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.66 [1.08; 2.57]
0.83 [0.21 ; 3.29 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 94% 723 moderate not evaluable TRAE leading to death (grade 5)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.06; 15.24]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.48 [0.02; 14.54]
0.72 [0.08 ; 6.23 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.87 [0.38; 1.95]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.58 [0.23; 1.44]
0.72 [0.40 ; 1.33 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.06; 15.67]
0.73 [0.08 ; 6.26 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Acute kidney injury TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
1.42 [0.11 ; 18.62 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.43 [0.11 ; 18.70 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.30 [0.08; 1.14]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.64 [0.22; 1.83]
0.48 [0.21 ; 1.09 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.96 [0.44; 35.74]
2.06 [0.30 ; 14.08 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 5% 723 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
1.42 [0.11 ; 18.62 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Colitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.43 [0.11 ; 18.70 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Constipation TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.96 [0.06 ; 15.40 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.43 [0.11 ; 18.70 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 9.70 [0.53; 178.83]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
4.92 [0.54 ; 44.97 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Dry skin TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.48 [0.02; 14.54]
0.48 [0.04 ; 5.30 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Dyspnoea TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
1.42 [0.11 ; 18.62 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.16 [0.01; 3.13]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.37 [0.91; 12.46]
0.99 [0.05 ; 18.91 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 71% 723 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.16 [0.01; 3.13]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.32 [0.03; 3.11]
0.25 [0.04 ; 1.51 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Hepatitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
1.42 [0.11 ; 18.62 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Hypersensitivity TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.43 [0.11 ; 18.70 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 3.82 [0.17; 85.21]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
2.81 [0.28 ; 27.87 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
1.42 [0.11 ; 18.62 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 3.82 [0.17; 85.21]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
2.25 [0.20 ; 25.75 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.92 [0.18; 87.59]
2.27 [0.20 ; 25.92 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.92 [0.18; 87.59]
2.82 [0.28 ; 27.94 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.06; 15.67]
0.73 [0.08 ; 6.26 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.16 [0.01; 3.13]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.32 [0.03; 3.11]
0.25 [0.04 ; 1.51 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 4.97 [0.57; 42.99]
2.24 [0.25 ; 19.91 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 24% 723 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.31 [0.03; 3.03]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.19; 4.88]
0.66 [0.18 ; 2.48 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Nausea TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2.95 [0.30; 28.63]
1.68 [0.25 ; 11.08 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.05 [0.00; 0.87]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.38; 2.51]
0.30 [0.02 ; 5.18 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 73% 723 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.05 [0.00; 0.87]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2.05 [0.89; 4.69]
0.42 [0.01 ; 15.25 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 83% 723 moderate not evaluable Pancytopenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.23 [0.01; 5.24]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.24 [0.01; 5.38]
0.24 [0.03 ; 2.14 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.43 [0.11 ; 18.70 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.43 [0.11 ; 18.70 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Pneumonia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 1.90 [0.06; 56.93]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.92 [0.17 ; 21.31 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.06; 15.24]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.48 [0.02; 14.54]
0.72 [0.08 ; 6.23 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.43 [0.11 ; 18.70 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.96 [0.06 ; 15.40 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.96 [0.06 ; 15.40 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Rash TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.16 [0.01; 3.13]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 3.73 [1.02; 13.61]
1.03 [0.05 ; 21.89 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 72% 723 moderate not evaluable Sepsis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.97 [0.02; 49.28]
0.96 [0.06 ; 15.40 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Skin exfoliation TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.95 [0.02; 47.96]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 1.95 [0.07; 58.51]
1.43 [0.11 ; 18.70 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Stomatitis TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.09 [0.01; 1.70]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2.00 [0.67; 5.97]
0.58 [0.03 ; 11.22 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 73% 723 moderate not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.47 [0.02; 14.15]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.48 [0.02; 14.54]
0.48 [0.04 ; 5.30 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable Vomiting TRAE (grade 3-4)detailed results JAVELIN ovarian 200 (A vs doxorubicin), 2021 0.31 [0.03; 3.03]
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 0.32 [0.03; 3.11]
0.32 [0.06 ; 1.58 ] JAVELIN ovarian 200 (A vs doxorubicin), 2021, JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 2 0% 723 moderate not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 08:30 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 7,248,247,249,250,251,246
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743